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MicroRNAs in Platelets: Should I 
Stay or Should I Go?
Sonia Águila, Ernesto Cuenca-Zamora, 
Constantino Martínez and Raúl Teruel-Montoya
Abstract
In this chapter, we discuss different topics always using the microRNA as the 
guiding thread of the review. MicroRNAs, member of small noncoding RNAs 
 family, are an important element involved in gene expression. We cover different 
issues such as their importance in the differentiation and maturation of megakaryo-
cytes (megakaryopoiesis), as well as the role in platelets formation (thrombopoi-
esis) focusing on the described relationship between miRNA and critical myeloid 
lineage transcription factors such as RUNX1, chemokines receptors as CRCX4, or 
central hormones in platelet homeostasis like TPO, as well as its receptor (MPL) 
and the TPO signal transduction pathway, that is JAK/STAT. In addition to platelet 
biogenesis, we review the microRNA participation in platelets physiology and 
function. This review also introduces the use of miRNAs as biomarkers of platelet 
function since the detection of pathogenic situations or response to therapy using 
these noncoding RNAs is getting increasing interest in disease management. Finally, 
this chapter describes the participation of platelets in cellular interplay, since extra-
cellular vesicles have been demonstrated to have the ability to deliver microRNAs 
to others cells, modulating their function through intercellular communication, 
redefining the extracellular vesicles from the so-called “platelet dust” to become 
mediators of intercellular communication.
Keywords: platelets, megakaryocytes, microRNAs, intercellular communication, 
microvesicles
1. Introduction
The discovery of noncoding RNAs, apart from raising new questions about the 
central dogma of molecular biology, has greatly contributed to the basic knowl-
edge of numerous diseases, and to their therapeutic utility [1]. Nowadays, nobody 
doubts that the so-called “junk genome,” a large DNA proportion of the genome 
[2], undoubtedly participates in the flow of genomic information [3] that gives rise 
to cellular functions and that frequent diseases are associated with malfunction of 
noncoding RNAs [4].
Although essential processes are common to all kind of cells, in physiological 
condition, each tissue or cell has unique features or responses that define their 
phenotype. These functions will be controlled by the gene expression patterns 
of that tissue and therefore by the regulatory mechanisms of such expression. 
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Thus microRNAs (miRNAs), which are a family of small noncoding RNAs, are an 
important element in gene-expression-regulation [5]. This function of miRNAs, 
which is exerted through repression of gene expression, is related to the specific 
miRNA expression, in a spacial and timely manner; in other words, it is tissue and/
or developmental stage-specific [6].
This becomes more important in a cell that lacks a nucleus, such as platelets, and 
therefore lacks the ability to regulate gene expression through canonical mecha-
nisms such as transcription factors (TFs) or epigenetic mechanisms of genome 
modification, for example, cytosine methylation or histone acetylation. In this 
scenario, miRNAs may acquire more prominence in the processes of gene regulation 
at a post-transcriptional level [7], not only during platelet production (throm-
bopoiesis), but also providing to the platelets with certain capacity to modulate 
their phenotype and consequently contribute to their ability to respond to external 
stimuli.
Historically, the study of hematopoiesis has been focused in general on the 
investigation of cytokine receptors and TFs, which ultimately govern the different 
membrane marker characteristics of each hematopoietic lineage, in a continu-
ous change in gene expression patterns. The TFs expressed by megakaryocyte 
(MK) progenitors that enable their engagement with the lineage are increasingly 
understood. During MK differentiation, the progression to specific hematopoietic 
pathways is influenced by changes in the levels of these factors. These changes are 
dynamic, and in this scenario, it is clear that the repressive action exerted by miR-
NAs on their targets, for example, TFs, may be one more element to pay attention to 
in hematopoiesis [8, 9].
Finally, as mentioned above, there is a certain specificity of miRNA expression 
at the tissue-cell level, but in recent years cellular communication mechanisms have 
also been described in which a transfer of content from cell to cell [10], through 
extracellular vesicles (EVs), for example, microvesicles or exosomes, can occur. 
Within the content of EVs, we can find genetic material such as miRNAs [11], thus 
making possible the regulation of gene expression at a distance. If we add to this the 
fact that platelets provide a large proportion of the total cellular miRNAs found in 
blood [12], in addition to the high correlation observed in miRNA profiles expres-
sion between plasma and platelets [13] and that most of the EVs that circulate in 
bloodstream come from platelets [14], their study from a pathophysiological point 
of view, as well as their possible use as a therapeutic tool, is very relevant.
In summary, in this chapter we intend to discuss different topics, always using 
the miRNA as the guiding thread of the review, which would cover issues such 
as their importance in the platelet biogenesis, as well as their participation in 
their (platelets’) physiology and function. This review will also introduce issues 
such as the use of miRNAs as biomarkers of platelet function, and the detection 
of pathogenic situations. Finally, this chapter will describe the participation of 
platelets in cellular interplay, since EVs have been demonstrated to have the ability 
to deliver their cargo to other cells, modulating their function through intercellular 
communication.
2. Biogenesis and function of miRNA
2.1 Biogenesis
The synthesis of miRNAs begins in the nucleus, through their transcription 
by RNA polymerase II, giving rise to a product called pri-miRNA, which has 
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a size range from several hundred nucleotides (nt), to several kilobases; this 
may depend on the miRNA gene location, that is, polycistronic, intronic, or 
introgenic. Still in the nucleus, pri-miRNA is processed into pre-miRNA by the 
Microprocessor catalytic complex, composed by Drosha and DGCR8. The first 
component is a nuclease with two RNAse III domains, which are responsible 
for cutting the pri-miRNAs. DGCR8, on the other hand, contains RNA-binding 
domains that stabilize the pri-miRNA for being processed by Drosha [15]. The 
pre-miRNA resulting structure is 3’overhang hairpin-like shape and it has a size 
of approximately 70 nt. Pre-miRNA will leave the nucleus, mainly by a RanGTP/
export 5-dependent mechanism and once in the cytoplasm will be reprocessed, by 
Dicer, resulting in a new ~22 nt size double-stranded form [16]. Of the two strands 
that form the mature-duplex pre-miRNA, one is the so-called “guide” strand and 
will be loaded into Argonaute (AGO), while the other strand may be degraded or 
even become functional too. Despite the fact that general aspects of the miRNA 
maturation pathway have been known for a long time, at present and due to 
structural studies, the functions of the macromolecular complexes involved are 
increasingly known in detail, giving a deeper understanding of their involvement 
in miRNA cytoplasmic processing [16, 17].
2.2 Function
The complete functional unit consists of the mature miRNA and the AGO 
protein, which recognizes by base pairing its target mRNA, mainly in the 3′ 
untranslated (3’UTR) region, and this union will induce both, an inhibition of 
mRNA translation in its first stages and a RNA decaying. The repressive action on 
translation is exerted by the initiation factors 4 A-I (eIF4A-I) and eIF4A-II. On the 
other hand, the mRNA decay is favored by the 5’mRNA deadenylation, followed by 
its decapping [18]. Finally, this leads to an indelible genetic silencing, which is often 
complex to study due to the intricate network and interactions that occur between 
different miRNAs and mRNAs, since a miRNA can have multiple target mRNAs, 
and a single mRNA can be cooperatively regulated by multiple miRNAs (Figure 1).
Figure 1. 
Outline of the processes involved both in miRNA biogenesis and in its function.
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3. Platelets miRNA repository
Since Landry et al. showed in 2009 that platelets have abundant and diverse 
miRNAs [19], numerous studies have analyzed the content of miRNA in platelets. 
We review the miRNAs detected in platelets, focusing especially on those detected 
with greater expression. First, we have to keep in mind that there are different 
technologies, therefore platforms, in which a high throughput miRNA analysis can 
be performed, such as microarray, nanostring, or RNA-seq [20]. We will not go 
into details about the technologies used, but we will rather give importance to the 
experimental conditions used, in terms of the platelets purity. Since the total RNA 
content in platelets, in absolute terms, is very low, compared to other blood cells 
[12], that is leucocytes, a possible contamination can alter or bias the results. Thus, 
we here focus on studies that performed a leukocyte depletion step by filtration 
or immunoselection. We summarize in a table (Table 1), the expression of the 40 
most expressed miRNAs from selected studies, in order to outline the miRNAs that 
coincide between them. To note, all the provided information comes from human 
Landry [19] Nagalla [23] Edelstein [21] and Simon [22] Teruel-Montoya [24]
1 miR-142-5p miR-223 miR-223 miR-126
2 miR-142-3p miR-26b miR-26a miR-223
3 miR-223 miR-26a miR-126 miR-142-3p
4 let-7a miR-23a miR-142-3p miR-26a
5 miR-185 miR-126 miR-16 let-7 g
6 let-7c miR-21 miR-92a miR-16
7 let-7i let-7f miR-21 miR-15b
8 let-7b miR-22 miR-103a miR-92a
9 miR-126 miR-24 miR-20a/b let-7a
10 miR-103a miR-720 let-7a let-7d
11 miR-320 miR-16 miR-24 miR-21
12 miR-30c miR-23b let-7 g miR-199a/b
13 miR-130a miR-142-3p miR-199a/b miR-451a
14 miR-26a miR-142-5p miR-15a miR-15a
15 miR-191 miR-191 let-7d let-7f
16 miR-30b miR-451a miR-30b miR-23a
17 miR-146a miR-30b let-7f miR-103a
18 miR-23b miR-15b let-7i let-7i
19 miR-21 let-7a miR-15b miR-20a/b
20 miR-23a miR-1826 miR-23a miR-24
21 miR-19a miR-17 miR-221 miR-191
22 miR-106a miR-103a miR-146a miR-25
23 miR-15b miR-106a miR-451a miR-19b
24 miR-20a miR-30c miR-19b miR-30b
25 miR-107 miR-130a miR-142-5p miR-221
26 miR-451a let-7 g miR-148b miR-148b
27 miR-222 miR-30a miR-191 miR-146a
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healthy subjects. While it is true that there may be differences in age, gender, or race 
[21, 22], we observe that there are 18 miRNA coincidences, that is, miR-223, miR-
126, miR-26a, miR-142-3p, miR-16, miR-21, miR-103a, let-7a, miR-24, miR-30b, 
let-7i, miR-15b, miR-23a, miR-146a, miR-451a, miR-142-5p, miR-191, and miR-
106b. With a lower degree of coincidence, there are five miRNA coincidences in four 
out of the five publications: let-7f, let-7d, miR-15a, let-7 g, and miR-720. In addi-
tion, there are 11 miRNA matches in at least 3 of the 5 datasets, that is, miR-103, 
miR-19b, miR-27b, miR-92a, miR-181a, miR-148a, miR-221, miR-25, miR-20a/b, 
and miR-151-5p.
The knowledge of the platelets-miRNA-cargo, as it is explained throughout the 
chapter, is important for understanding not only platelet biogenesis and physiol-
ogy itself, but also MK function. Thus, platelets represent a faithful reflection of 
the physiological state of its progenitor with the advantage that platelets are much 
more accessible than the MKs. A better understanding of the physiological state of 
the platelet will undoubtedly help us to detect oscillations that may be pathologi-
cal, and it is here that miRNAs can help us in diagnosis, prognosis, as well as to 
follow-up the disease progression. In addition to their great accessibility, circulat-
ing and platelet miRNAs are relatively easy to measure [25] and their physical-
chemical properties make them good candidates for being used as biomarkers 
[26]. Furthermore, platelets are an important source of circulating miRNAs that 
can remotely regulate gene expression in other cells, such as macrophages or 
endothelial cells.
4. Role of miRNA in megakaryopoiesis and thrombopoiesis
Megakaryopoiesis and subsequent thrombopoiesis occur through a series of 
complex biological processes. First, MK precursors developed from hematopoietic 
stem cells (HSCs) initially proliferate, and then differentiate into mature polyploid 
MKs, which eventually release platelets. Thus, we cannot ignore great peculiarities 
Landry [19] Nagalla [23] Edelstein [21] and Simon [22] Teruel-Montoya [24]
28 miR-151-5p miR-146b miR-25 miR-27b
29 miR-24 miR-34b miR-106b miR-151a
30 miR-625 miR-106b miR-423-5p miR-181a
31 miR-671 miR-15a miR-27b miR-720
32 miR-29a miR-374a miR-340 miR-29a
33 miR-22 miR-20a miR-181a miR-142-5p
34 miR-16 miR-185 miR-151-5p miR-423
35 miR-199a/b miR-146a miR-720 miR-125a
36 miR-106b let-7i miR-199a-5p miR-374a
37 miR-146b let-7c miR-101 miR-106b
38 miR-151-3p miR-19a miR-374b miR-29c
39 miR-98 let-7d miR-29a miR-335
40 miR-148b miR-27a miR-148a miR-148a
Underlined those miRNAs that appear in the top 40 in all the studies.
Table 1. 
Comparison of the 40 most expressed miRNA in platelets ranked by expression.Rank.
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of platelets, in particular the fact that they are anucleate cells derived from MKs 
and that their content is the reflection of their parental cells, including the miRNA 
cargo. Accordingly, we consider it essential to describe the role of miRNAs in 
platelet and the megakaryopoiesis itself.
4.1 miRNAs in megakaryopoiesis
Megakaryopoiesis takes place primarily in the bone marrow. To understand this 
process in a simple way, it can be separated into two phases: the proliferative phase, 
in which the expansion of the MK precursors takes place, and the maturation 
phase, in which the two main events of this lineage occur. The first is at the nuclear 
level, the polyploidization by endomitosis, and the second is the cytoplasmic 
maturation [27].
In the last decade, many miRNAs have been described that can regulate or be 
regulated by TFs implicated in megakaryopoiesis (Table 2). For practical reasons, 
we only focus on some of the regulatory miRNAs. The miR-144/451 cluster, the 
miRNA most expressed in erythrocytes [12], can be repressed by RUNX1 dur-
ing megakaryopoiesis. In myeloid differentiation, RUNX1 takes on a major role, 
since it represses erythroid lineage-specific genes and at the same time activates 
the transcription of specific genes of the MK lineage [28], and it is known to 
regulate MK polyploidization [29] and cytoskeleton rearrangement in the process 
of MK maturation formation [30]. On the other hand, it has been shown that 
miR-144/451 locus is activated by GATA1 [31–33], which primarily promotes 
erythropoiesis, but which has also been described as important for megakaryo-
poiesis. Another well-studied TF-miRNA interaction is mirR-27a and Runx1. 
miR-27a can repress Runx1 expression in mice. During megakaryopoiesis, Runx1 
and miR-27a are engaged into a feedback positive loop regulation of miR-27a 
expression by Runx1. Ben-ami et al. also observed in K562 a human immortal-
ized myelogenous leukemia cell line, and upon megakaryocytic differentiation 
by 12-o-tetradecanoylphorbol-13-acetate (TPA), that RUNX1 binds to a putative 
miR-27a regulatory region and upregulates its expression [34]. RUNX1-miRNA 
relationship goes in the direction of miRNA regulation by RUNXI, but RUNXI 
can also be regulated by miRNA; in this sense, miR-9 can regulate the expression 
of RUNX1. The increase of this miRNA in human MEG-01 and DAMI cell lines, 
both megakaryoblast phenotype cell lines, has shown a decrease in RUNX1 at both 
mRNA and protein levels [35]. Furthermore, an inverse level of expression in 
RUNX1 and miR-9 has been observed in MKs derived from umbilical cord blood 
(MKCB) and peripheral blood (MKPB) [35, 36]. We can also mention two more 
cases: (i) PLZF, a transcription factor whose expression increases during mega-
karyopoiesis, can downregulate miR-146a, which represses CXCR4 [37]; there-
fore, PLZF activates CXCR4 translation and the increase in CRCX4 can induce 
MK migration through bone marrow. (ii) ETS1 and MEIS1, both, are TFs with 
well-known functions in hematopoiesis; ETS1 is upregulated in megakaryocyto-
poiesis, regulating MK-specific gene promoters, such as platelet factor 4, GATA-2 
or GPIIb, indicating that ETS1 promotes MK differentiation [38], and MEIS1 is 
vital for megakaryopoiesis and thrombopoiesis from human pluripotent stem cells 
[39]. MiR-155 downregulates both ETS1 and MEIS1, in HSCs, whereas miR-155 
expression rapidly declines during TPO-induced megakaryocytic differentia-
tion [40], thus favoring the process of megakaryocyte differentiation through 
ETS1 and MEIS1. As we have seen, there is evidence of the possible regulation of 
megakaryopoiesis by miRNAs, a connection between TF and miRNAs, and that 
the expression of the miRNA-coding genes is affected [41]. We do not know if this 
is due to a causal relationship or a consequence of the maturation process, perhaps 
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TF miRNA Function/effect Ref.
RUNX1 miR-
144/451
miR-144/451 cluster is repressed by RUNX1 during 
megakaryocytopoiesis
[28]
miR-9 miR-9 represses RUNX1 during megakaryocytic 
differentiation
[35]
miR-9 expression is higher in MKs from cord blood than 
MKs from peripheral blood, as opposed to RUNX1
[35, 49]
miR-27a In megakaryocytic differentiation, miR-27a is 
stimulated by RUNX1, and it can directly target RUNX1 
(negative feedback loop)
[34]
FLI1 miR-145 miR-145 downregulates FLI1 during megakaryocytic 
differentiation. This increases MKs production compared 
to erythrocytes
[50]
FLI1 may target back miR-145 promoter, creating a 
negative feedback loop
[51]
GATA1 miR-
144/451
GATA1 activates miR-144/451 locus [31–33]
miR-138 miR-138 expression is increased by GATA1, and miR-138 
represses BCR-ABL1 fusion gene
[52, 53]
HOXA1 miR-10a miR-10a represses HOXA1. miR-10 is downregulated in 
human CD34+ bone marrow progenitor-derived MKs
[54]
In cord blood HSCs, miR-10a knockdown increases 
HOXA1 expression and stimulates megakaryocytic 
differentiation, even in the absence of TPO
[55]
HOXA11 miR-181a It is predicted that miR-181a targets HOXA11 [56]
ETS1
MEIS1
miR-155 miR-155 downregulates both ETS1 and MEIS1. In 
human HSPCs, during TPO-induced megakaryocytic 
differentiation, miR-155 expression is rapidly declined
[40]
ETV6 miR-181a It is predicted that miR-181a targets ETV6 [56]
miR-181a targets ETV6/RUNX1 gene fusion, observed in 
acute lymphoblastic leukemia
[57]
miR-320a miR-320a is downregulated by ETV6/RUNX1 gene 
fusion, and targets survivin, an antiapoptotic protein
[57, 58]
miR-494 miR-494 is downregulated by ETV6/RUNX1 gene fusion, 
and targets survivin, an antiapoptotic protein
[57, 58]
MAFB miR-130a miR-130a, which represses MAFB, is downregulated 
during human megakaryocytic differentiation
[54]
GFI1 miR-22 miR-22 downregulates GFI1, stimulating myeloid and 
lymphoid differentiation
[59, 60]
Overexpression of miR-22 increased K562 
megakaryocytic differentiation, while miR-22 knockout 
inhibited this process induced by PMA (and upregulates 
GFI1)
[60]
miR-22 knockout mice showed less of both immature 
and mature MKs in bone marrow and more GFI1 
expression
[60]
GFI1B miR-22 GFI1B, a GFI1 paralog without miR-22 seed sequence, 
is highly expressed in MK lineage and in K562 cells, and 
promotes MK and erythrocyte differentiation
[60]
In this case, miR-22 may regulate GFI1B indirectly 
through GFI1 because GFI1 and GFI1B could compete for 
DNA occupancy
[60]
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both, but what we do know is that it can have a side effect on the expression of 
many other genes.
Besides the relationships of TFs and miRNAs in megakaryopoiesis, other miR-
NAs have been described as complex effectors of megakaryopoiesis, for example the 
miR-146 family, which includes miR-146a and miR-146b. Specifically, miR-146a, 
a miRNA closely related to inflammatory diseases, seems to play an important 
role in the development of normal hematopoiesis. Thus, deficient miR-146a mice, 
stands out for the phenotypic features of abnormal hematopoiesis, highlighted 
by bone marrow myelofibrosis [42]. Its complex role in megakariopoiesis lies in 
part in some controversy about the role of this miRNA in this process. It has been 
described that miR-146a expression is high during induced megakaryocytopoiesis 
in vivo in murine model and in vitro in human cell culture; however, enforced 
miR-146a expression has minimal effects on the process [41]. On the other hand, 
it has been reported that miR-146a expression is downregulated when human cord 
blood-derived CD34+ cells are induced to differentiate into MKs [37], but miR-146a 
overexpression impaired megakaryocytopoiesis [41] and knockdown of miR-146a 
in mouse HSCs resulted in increased MKs in the bone marrow [43, 44]. This dis-
agreement may be due to differences in experimental conditions and the differences 
between human and murine models that have been used, but this does not detract 
from the fact that miR-146a may actually have an effect on megakaryopoiesis. The 
other member of miR-146 family, miR-146b, regulates directly and indirectly, 
TF miRNA Function/effect Ref.
FOSB miR-22 FOSB stimulates miR-22 expression in K562 stimulated 
by PMA, required for megakaryocytopoiesis
[61]
miR-22 expression could be regulated by opposing 
activities of FOSB and GFI1
[62]
PLZF 
(ZBTB16)
miR-146a ZBTB16 downregulates miR-146, which represses 
CXCR4.
[37]
miR-146a and CXCR4 (and its ligand SDF1) regulate 
HSC homing, MK proliferation, differentiation, and 
maturation
[63, 64]
EVI1 miR-133 EVI1 overexpression upregulates miR-133, in acute 
myeloid leukemia cells
[65]
miR-133 downregulates EVI1, making a negative 
feedback loop
[66]
miR-1 EVI1 overexpression upregulates miR-1, which increases 
cell proliferation, in acute myeloid leukemia cells
[65]
miR-449a miR-449a is repressed by EVI1, and this microRNA 
downregulates NOTCH1 and BCL2. In this way, miR-
449a expression decreases cell viability and increases 
apoptosis of MECOM overexpressing leukemic cells
[67]
ABL1: ABL proto-oncogene 1, non-receptor tyrosine kinase; BCL2: BCL2 apoptosis regulator; BCR: BCR activator of 
RhoGEF and GTPase; CXCR4: C-X-C motif chemokine receptor 4; ETS1: ETS proto-oncogene 1; ETV6: ETS variant 
transcription factor 6; EVI1: ecotropic viral integration site 1; FLI1: Fli-1 proto-oncogene, ETS transcription factor; 
FOSB: FosB proto-oncogene, AP-1 transcription factor subunit; GATA1: GATA binding protein 1; GFI1: growth 
factor independent 1 transcriptional repressor; GFI1B: growth factor independent 1B transcriptional repressor; 
HOXA1: Homeobox A1; HOXA11: Homeobox A11; HSCs: hematopoietic stem cells; HSPCs: hematopoietic stem and 
progenitor cells; MAFB: MAF BZIP transcription factor B; MECOM: MDS1 and EVI1 complex locus; MEIS1: Meis 
Homeobox 1; MKs: megakaryocytes; NOTCH1: notch receptor 1; PLZF: promyelocytic leukaemia zinc finger; PMA: 
phorbol myristate acetate; RUNX1: RUNX family transcription factor 1; SDF1: stromal cell-derived factor 1; TPO: 
thrombopoietin; ZBTB16: zinc finger and BTB domain containing 16.
Table 2. 
Transcription factors-miRNA relationship in megakaryocytic differentiation.
9MicroRNAs in Platelets: Should I Stay or Should I Go?
DOI: http://dx.doi.org/10.5772/intechopen.93181
through GATA-1, the expression of the platelet-derived growth factor receptor α 
(PDGFRA), in phorbol 12-myristate 13-acetate (PMA)-differentiated K562 cells. 
In addition, the expression of miR-146b increases in CD34+ hematopoietic stem/
progenitor cells undergoing megakaryocytic differentiation; at the same time, 
the expression of PDGFRA decreases [45]. Finally and also in CD34+ derived MK 
differentiation assays, other researchers suggest that miR-28 plays a negative role in 
the differentiation of MK precursors. Through miR-28 transduction experiments 
on human CD34+ cells, with subsequent differentiation to MKs, using thrombo-
poietin (TPO), they observed a reduction of more than 50% in the number of MKs 
with proplatelets. This is, in part, explained by a repression of MPL gene expression, 
which encodes for the TPO receptor [46]. In relation with TPO, the expression of 
miR-150 has been described to increase with this hormone [47], and assays  consisting 
in  overexpression of miR-150, seem to suggest that elevated levels of miR-150 
enhanced both in vitro and in vivo megakaryocyte differentiation at the expense of 
erythroid differentiation [48].
4.2 miRNAs in thrombopoiesis
Thrombopoiesis is the process by which platelets are generated from MKs 
During this process, microtubules mediate elongation of the MK extensions (pro-
platelet, Figure 2) and granule trafficking from MKs to nascent platelets [68].
As we have already mentioned, the TFs cited above are not only of great impor-
tance in megakaryopoiesis, but also in thrombopoiesis. It is very intuitive to think 
that the miRNAs that can regulate these TFs will also affect thrombopoiesis. Since 
many of the mutations described in RUNX1, FLI1, GATA1, GFI1B, ETV6, EVI1, 
and HOXA11 have been associated with variable thrombocytopenia [69]. The same 
effect can be expected for both cases, in the repression of TF-coding-gene expres-
sion, and when a mutation is observed that causes a loss of function in the same 
TF. Therefore, as far as possible, we will not be redundant with those relationships 
of miRNAs and TFs already described above (Table 2) that have repercussions 
on thrombopoiesis. In addition miRNAs can exert a quantitative regulation of 
Figure 2. 
Megakaryocytes and proplatelets [21]. CD34+ hematopoietic stem/progenitor cells obtained from human 
cord blood and differentiated to MKs and proplatelets. At day 14 of culture, MKs show proplatelet formation 
(pointed with red arrows). The color code of the fluorescence staining is as follows: DNA (DAPI, purple-blue), 
α-tubulin (green), and actin (red).
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megakaryopoiesis, which will eminently translate into a regulation, a priori quanti-
tative, of platelet formation.
In this part, we discuss those miRNAs that have been described as regulatory 
entities for the expression of genes encoding proteins of the Janus kinase (JAK)-
signal transducer and activator of transcription (STAT) pathway, which is a fun-
damental pathway that controls platelet homeostasis. Indeed, mutations in those 
genes of this pathway, such as JAK2V617F in JAK2 and mutations in MPL exon 10, 
that cause a constitutive activation of the pathway, developing a thrombocytosis 
phenotype, named essential thrombocythemia (ET), have been described. As 
stated above, it has been reported that miR-28 targets the 3’UTR region of MPL, 
inhibiting its translation and probably contributing to reduce the number of MKs 
forming proplatelets [46], and therefore platelets number. The regulation of JAK2 
by miRNAs in the context of thrombopoiesis is unknown, but Navarro et al. have 
described direct regulation of JAK2 by miR-135a by targeting its 3’UTR region in 
Hodgkin lymphoma [70]. Interestingly, the same author in another study described 
that SOCS1 and SOCS3, which are negative regulators of the JAK/STAT pathway, are 
directly regulated by miR-203 and miR-221 (a highly platelet expressed miRNA), 
respectively [71]. In addition, the levels of expression of these two miRNAs main-
tain a highly inverse correlation with the levels of SOCS1 and SOCS3 in platelets 
from patients with ET, suggesting that, in combination with a epigenetic regulation, 
those miRNAs could explain the SOCS1 and SOCS3 downregulated state in ET 
JAK2V617-negative patients, activating JAK/STAT pathway [71].
Finally and besides the JAK/STAT pathway, Rowley et al. observed in a specific 
MK Dicer-deficient murine model reduced levels in most platelet miRNAs, which 
lead to an altered profile of mRNA that apart from the functional consequences 
related to the increase of Itga2b (αIIb) and Itgb3 (β3), also provokes a mild throm-
bocytopenia [72].
5. miRNAs in platelet physiology and function
In previous sections, we dealt with quantitative changes observed in the 
production of platelets by miRNA. In contrast, in this section we deal with the 
qualitative changes that these can produce in platelets. The role of miRNAs in 
hemostasis is not well known, and most of the studies have focused on platelets 
as the central elements of primary hemostasis. Indeed, the first study reporting 
the presence of miRNAs in platelets was performed in 2008 in healthy controls 
and patients with polycythemia vera [73]. Of note, platelet miRNA levels have 
been recently correlated with platelet maturity and platelet function in patients 
with essential thrombocythemia [74]. Afterwards, many studies reported the 
presence of a large number of miRNAs in platelets [75]. Importantly, Landry et al. 
published a landmark paper that established miRNAs as important effectors of 
platelet function [19]. The authors showed that miRNAs were not only inherited 
from megakaryocytes, but platelets were also able to produce mature miRNAs 
from pre-miRNA since they contain all the machinery permitting the miRNA 
maturation (i.e., Dicer, TRBP2, and Ago2). Different circumstances make uneasy 
the study of miRNA function in platelets and until now their role still remains 
elusive. The main reasons are that platelets do not perform transcription and in 
vitro experiments with platelets are difficult to develop. Since it has been shown 
by different reports that pre-mRNA maturation as well as de novo translation 
occurs in platelets after agonist activation such as thrombin [76, 77], different 
studies have investigated if the same happens for miRNAs since, as mentioned 
above, they contain the necessary molecular tools for this process. The results 
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are controversial since whereas Corduan et al. showed that thrombin does not 
provoke miRNA maturation [78], other studies have shown that agonists such 
as thrombin receptor-activating peptide, collagen, and adenosine diphosphate 
(ADP) regulate miRNA levels [79]; the difference between both studies may 
reside in the incubation time, 10 min versus 120 min in the latter study. Thus, 
as suggested by Corduan et al., quantitative changes in miRNA level unlikely 
modulate de novo protein synthesis in the minutes following platelet activation, 
the regulation may rather occur during the whole platelet lifetime by mechanisms 
that are still to be fully characterized [77]. Upon activation, platelets are able to 
synthesize proteins such as interleukin-1β (IL-1β), plasminogen activator  inhibitor-1 
(PAI-1), or thrombospondin-1 (TSP-1). Interestingly, Miao et al. found that 
platelet activation with thrombin for 30 minutes modified the expression of 103 
miRNAs [80]. Among these miRNAs, the authors showed that miR-27b levels, 
that target TSP-1 [81], decreased after thrombin activation, while TSP-1 increased. 
The authors also showed using a patented platelet transfection reagent (Ribojuice) 
that transfection of platelets with a miR-27b mimic decreased TSP-1 levels after 
thrombin activation [80]. Additionally, Corduan et al. suggested that several de 
novo translated proteins, among them integrins αIIb and β3, may be regulated by 
platelet-expressed miRNAs [78]. Interestingly, Rowley et al. demonstrated that in 
a conditional mouse model (MK) of Dicer1 deficiency, which provokes a reduc-
tion of certain miRNA expression levels, mice have high levels of platelet αIIbβ3, 
elevated platelet reactivity, shortened tail-bleeding time, and reduced survival 
following collagen/epinephrine-induced pulmonary embolism [72]. In particular, 
the authors suggest that miR-128, miR-326, miR-331, and miR-500 may regulate 
αIIbβ3 expression (Table 3). Recently, Middleton et al. demonstrated that sepsis 
increased αIIbβ3 translation in a cecal ligation and puncture (CLP) mouse model; 
it would be of interest to test if miRNAs involved in the regulation of these two 
proteins are downregulated and may be implicated in αIIbβ3 overexpression [82]. 
miRNA. Target Ref.
miR-223 P2Y12
Factor XIII
[19, 87]
miR-126-3p ADAM9
PLXNB2
[83]
miR-96 VAMP8 [88]
miR-21 WASP [89]
miR-27b TSP-1 [80]
miR-30c PAI-1 [90]
miR-181a RAP1B [91]
miR-128
miR-500
miR-331
miR-326
αIIβ
αIIβ,β3
αIIβ,β3
αIIβ
[72]
miR-24 αIIβ [78]
miR-148a TULA-2 [92]
miR-376c PC-TP [21]
miR-26b
miR-140
SELP [93]
Table 3. 
miRNA-targets associated with platelets functionality.
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Indeed, Szilágyi et al. recently studied the regulation of miRNAs in a CLP model 
and observed an important dysregulation of miRNAs in platelets that may explain 
the pro-thrombotic phenotype caused by this pathology.
Besides pathological conditions, genetic factors may also alter miRNA levels. For 
example, miR-126 rs4636297 SNP drives the efficiency of miR-126-3p transcription 
and has been associated with several plasma markers of platelet reactivity such as 
P-selectin (SELP) or PAF4 suggesting that lower miR-126-3p platelet levels would 
lead to lower platelet reactivity [83]. Zhou et al. recently showed another potential 
regulatory pathway for miR-126-3p [84]. The authors discovered that platelets from 
patients with diabetes mellitus (DM) type 2 had higher levels of long noncoding 
RNA metallothionein 1 pseudogene 3 (MT1P3) than healthy controls. Interestingly, 
MT1P3 is able to sponge miR-126-3p and provoke an overexpression of P2Y12. This 
mechanism would additionally explain the high levels of ADP receptor observed in 
DM2 patients.
As indicated previously, investigating the role of miRNAs in platelet is some-
times an arduous task given the fact that basic cellular assays such as transfection 
or cell culture are difficult to perform. Investigators are trying to circumvent these 
problems by developing/adapting transfection reagent [80, 85], but also as nicely 
shown by García et al. by using alternative approaches [86]. In this paper, the 
authors demonstrated by using platelet-like structures obtained by differentiating 
human HSC CD34+ that miR-126-3p is involved in platelet function by regulating 
Plexin B2 (PLXNB2), an actin dynamics regulator [86]. The use of this kind of 
technology may help to better define the role of miRNAs in platelets.
6.  Platelets-derived miRNA as biomarkers in pathophysiological 
conditions
Interestingly, platelet miRNAs are the major source of the circulating miRNA 
pool. Therefore, circulating miRNAs may be interesting biomarkers of disease 
and of diverse pathophysiological conditions [13]. Indeed, platelets have been 
implicated in pathological processes such as cardiovascular disease (CVD) [94], 
for example, myocardial infarction (MI), hypertension, stroke, atrial fibrillation, 
thrombosis or atherosclerosis, and another pathologies, for example, sepsis or dia-
betes. Platelet activation plays an important role in the development of the different 
pathological cardiovascular situations mentioned above. On the other hand, in 
situations such as sepsis, platelet activation may be a consequence of the disease. In 
one way or another, platelet activation is essential in these pathologies and miRNAs 
could be used as a molecular biomarker of this process [13].
miRNAs, whose expression in platelets is consensually high, have been described 
as independent biomarkers in CVD. For example, let-7 g and miR-191 are inde-
pendent biomarkers of chronic kidney disease among patients with hypertension 
[95]. Also, miR-22 and miR-223 were reduced in hypertensive patients with 
cardiovascular complication being negatively correlated with systolic blood pres-
sure. Furthermore, miR-126 levels were indicative of cardiovascular disease in 
this patient cohort [96]. miR-21 has been demonstrated to inhibit inflammatory 
responses in the early phase of MI by targeting KBTBD7 and impairing MKK3/6 
activation in immune cells, which subsequently prevented excessive scar formation 
and improving cardiac function in mice [97].
A special mention should be made of miR-223, abundantly expressed in platelets 
and highly detected in plasma. This miRNA has been involved in the pathogenesis 
of different cardiovascular diseases through its effect in platelet reactivity and in 
endothelial cells [98, 99]. Furthermore, miR-223 may become a reporter of the 
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efficacy of anti-platelet therapy, since it was described that circulating miR-223 may 
serve as a novel biomarker to assess clopidogrel responsiveness in troponin-negative 
non-ST elevation acute coronary syndrome patients [100]. Therefore, platelet-
derived miRNAs have been related with different cardiovascular diseases and might 
have important roles as biomarkers not only for cardiovascular disease susceptibil-
ity, but also for its prognosis and treatment.
Finally, and as mentioned above, platelets-derived miRNAs can also be helpful 
from the point of view of biomarkers in other pathological situations such as sepsis 
or diabetes. Little is known about the regulation of miRNAs in platelets; conditions 
such as sepsis may play an important role. Indeed, septic platelets showed  
an altered miRNA profile and reduced platelet miR-26b correlated with sepsis 
severity and mortality [101]. Therefore, it could become a useful biomarker to 
indicate the high state of platelet activation in this disease. Other pathological 
conditions may also alter miRNA levels and impact platelet function. In diabetes, 
calpain, which is increased in platelets, may cleave Dicer, decreasing the levels of 
several miRNAs such as miR-223 that may affect functional targets such as the  
purinergic ADP receptor P2Y12, ultimately promoting the development of throm-
bosis [19, 87]. Other miRNAs were also found to be altered in diabetes. Fejes et al. 
showed that miR-26b levels were reduced in DM2 patients with an impact in the 
levels of SELP [93].
7. Involvement of platelets in intercellular communication
EVs were discovered by Peter Wolf in 1967 and named as “platelets dust” 
[102]. EVs are basically divided into exosomes, having the smallest diameter size 
from 30 to 100 nm; apoptotic bodies, which are larger in size (1–5 μm), released 
during apoptosis; and microvesicles or microparticles ranging in size from 0.1 
to 1 μm. Microparticles are cell-derived vesicles that lack the synthetic capac-
ity and may contain proteins, mRNAs, miRNAs, and cytoskeletal components. 
Platelet-derived microparticles (PMPs) are the most abundant microparticles 
in circulation and they can be produced from platelet itself or from megakaryo-
cytes. CD42+, CD41+ CD61+/CD31− are some surface markers to identify PMPs, 
and phosphatidylserine exposure in the surface; whereas CD63 is a marker for 
platelet exosomes [103]. PMPs have different functions and can be released 
spontaneously depending on αIIβ3 integrin and cytoskeletal turnover. Platelets 
activation enhances MPs shedding, and depending on the stimulus or stress, 
differences in MPs cargo or number have been characterized. Indeed, increased 
PMPs have been described in myocardial infarction, hypertension, thrombosis, 
sepsis, diabetes, and other pathologies. Additionally, the platelet activation 
with different agonists showed that miR-223 was the most abundant miRNA in 
all samples, and 46 miRNAs were common to all conditions. An enrichment of 
these 46 miRNAs (in particular, miR-451a and miR-21) was observed in PMPs 
compared with platelet cargo. Interestingly, platelet activation by CRP (GPVI 
agonist) generated fourfold more vesicles than the stimulation with ADP, PAR1, 
or PAR4. Furthermore, platelets stimulated with thrombin shed MPs containing 
AGO2 and miR-223 complexes that were internalized by endothelial cells (ECs) 
targeting some genes such as FBXW and EFNA1 [104]. Indeed, miR-223 from 
PMPs regulated ECs apoptosis targeting insulin-like growth factor 1 receptor 
[105]. These MPs were also internalized by ECs progenitors in culture [106]. 
Importantly, PMPs are not only uptaken by endothelial cells. These micropar-
ticles play different roles in coagulation and thrombosis, immune response and 
endothelial senescence and permeability. Thus, PMPs containing miR-126-3p 
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were internalized by macrophages improving their phagocytic capacity, and 
regulating mRNAs of cytokines or chemokines [107]. Platelets also have a 
role beyond hemostasis like cancer. Hence, platelets and PMPs are important 
in tumor progression. MiR-223 from PMPs increased in lung cancer patients 
promoting its invasion [108]. However, Michael et al. have described that PMPs 
were infiltrated in the solid tumor promoting tumor cells apoptosis through inhi-
bition of mitochondrial function by miR-24, one of the most abundant miRNAs 
in these MPs [109].
Platelets-derived exosomes also have an important role in miRNA transference. 
Plasma exosomes enriched in miR-223, miR-339, and miR-21 were shed before 
thrombosis in a stenosis murine model, resulting also increased in platelets from 
a murine stenosis model before thrombosis. These miRNAs were transferred to 
vascular smooth muscle cells (VSMCs) inhibiting PDGFRβ, involved in cellular 
proliferation [110]. The inhibition of PDGFRβ was observed in vivo as well [111]. 
Nevertheless, Zeng and coworkers found that activated platelet internalization by 
VSMCs rather than MPs increased miR-223 levels promoting VSMCs differentia-
tion. Platelets from diabetic mice had reduced miR-223 levels and consequently 
increased VSMCs hyperplasia [112].
The phenomenon of horizontal miRNA transference by platelets and 
microvesicles internalization by ECs, macrophages, VSMCs, cancer cells, and 
other cells has been described in hepatocytes regulating their proliferation 
[113]. Activated platelets due to myocardial infarction lose the expression of 
specific miRNAs. Thus, some of these miRNAs were transferred to ECs in a 
microvesicle-dependent manner. In particular, miR-320b was transferred to 
ECs regulating the expression of ICAM-1 modulating adhesion to their surface 
[114]. Therefore, platelet miRNA transference has a pivotal role in the influence 
of intercellular signaling and gene expression reprogramming of different cells 
and in different pathophysiological situations. Moreover, we cannot exclude the 
emerging role of other noncoding RNAs such as YRNAs, long noncoding RNAs, 
and circular RNAs in platelets and in the intercellular communication [115] 
(Figure 3).
Figure 3. 
Graphical abstract.
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8. Conclusions
Collectively, the data presented in this chapter indicate that miRNAs have a 
pivotal role in all platelet states, from their generation regulating megakaryocytes 
maturation, mainly through transcription factors to their function influencing 
platelet response under activation (Figure 3). Interestingly, miRNAs are important 
not only for platelet biology, but also because they reflect the platelet status. Thus, 
platelet miRNAs are used as biomarkers for pathological situations or anti-platelet 
therapy because they represent the major contribution to circulating miRNA pool. 
Moreover, miRNAs from platelets may regulate the function of others cells (VSMC, 
ECs, immune cells, or tumor cells) by intercellular communication mainly through 
microparticles. Thus, platelet miRNAs have a great potential for future research as 
therapeutic tools and as biomarkers of disease. Additionally, their role as modula-
tors of platelet function still has to be fully investigated to confirm that their pres-
ence in platelets is not a mere inheritance from MKs with any real impact in platelet 
biology.
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